Community-acquired Bacterial Pneumonia (CABP) Treatment Drugs Market, by Drug Class (Pleuromutilin Antibiotic, Cephalosporin, Glycylcycline, Oxazolidinone, Ketolide, and Others), by Dose Form (Solution and Tablet), by Route of Administration (Oral and In

Community-acquired Bacterial Pneumonia (CABP) Treatment Drugs Market, by Drug Class (Pleuromutilin Antibiotic, Cephalosporin, Glycylcycline, Oxazolidinone, Ketolide, and Others), by Dose Form (Solution and Tablet), by Route of Administration (Oral and Intravenous), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Community-acquired bacterial pneumonia (CABP) is most common acute respiratory illnesses among various infections triggering sepsis. Microbiologically, bacteria are common agents causing pneumonia, with Streptococcus pneumoniae being the most common cause worldwide. CABP is the most common infectious causes of illness and hospitalization, especially in the geriatric population. For instance, according to the National Center for Biotechnology Information (NCBI), in March 2020, the incidence of community-acquired pneumonia (CAP) in the U.S. is more than 5 million per year.
.
Market Dynamics
Inorganic strategies amongst key players are strengthening the companies’ market share in global community-acquired bacterial pneumonia (CABP) treatment drugs market. For instance, in 2017, Avir Pharma Inc. (Avir), an affiliate of the Laboratoire RIVA Group, entered into a Canadian distribution and license agreement with Basilea Pharmaceutica Ltd. for its antifungal Cresemba (isavuconazole) and antibiotic Zevtera (ceftobiprole). Avir plans to apply for a marketing authorization for isavuconazole in Canada. Zevtera is already approved by Health Canada for the treatment of adult patients with hospital-acquired pneumonia (HAP) and for the treatment of community-acquired pneumonia (CAP) and will be purchasing product from Basilea and will commercialize in Canada.
However, antibiotic resistance in drugs is hampering the market growth. For instance, according to an article published in November 2021 in the National Center for Biotechnology Information (NCBI), in pneumococcal pneumonia, beta-lactam as monotherapy may not be optimal therapy even if bacteria remain susceptible to the beta-lactam. Therefore, antibiotic resistance are expected to restrain the global community-acquired bacterial pneumonia (CABP) treatment drugs market.
Key features of the study:
This report provides in-depth analysis of the global community-acquired bacterial pneumonia (CABP) treatment drugs market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global community-acquired bacterial pneumonia (CABP) treatment drugs market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
Key companies covered as a part of this study are Nabriva Therapeutics, Paratek Pharmaceuticals, Inc., Melinta Therapeutics, Inc., Allergan plc, Bayer AG, Lupin Pharmaceuticals, Inc., Mylan N.V., Sanofi S.A., Pfizer Inc., Dainippon Sumitomo Pharma, Takeda Pharmaceutical Company Limited, and Basilea Pharmaceutica International AG.
Insights from this report would allow marketers and management authorities of companies to make informed decisions regarding future drug launches, drug class up-gradation, market expansion, and marketing tactics
The global community-acquired bacterial pneumonia (CABP) treatment drugs market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global community-acquired bacterial pneumonia (CABP) treatment drugs market.
Detailed Segmentation:
Global Community-Acquired Bacterial Pneumonia (CABP) Treatment Drugs Market, By Drug Class:
Pleuromutilin Antibiotic
Cephalosporin
Glycylcycline
Oxazolidinone
Ketolide
Others
Global Community-acquired Bacterial Pneumonia (CABP) Treatment Drugs Market, By Dose Form:
Solution
Tablet
Global Community-acquired Bacterial Pneumonia (CABP) Treatment Drugs Market, By Route of Administration:
Oral
Intravenous
Global Community-acquired Bacterial Pneumonia (CABP) Treatment Drugs Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Community-acquired Bacterial Pneumonia (CABP) Treatment Drugs Market, By Region:
North America
By Drug Class:
Pleuromutilin Antibiotic
Cephalosporin
Glycylcycline
Oxazolidinone
Ketolide
Others
By Dose Form:
Solution
Tablet
By Route of Administration
Oral
Parental
Topical
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
U.S.
Canada
Latin America
By Drug Class:
Pleuromutilin Antibiotic
Cephalosporin
Glycylcycline
Oxazolidinone
Ketolide
Others
By Dose Form:
Solution
Tablet
By Route of Administration
Oral
Parental
Topical
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
Europe
By Drug Class:
Pleuromutilin Antibiotic
Cephalosporin
Glycylcycline
Oxazolidinone
Ketolide
Others
By Dose Form:
Solution
Tablet
By Route of Administration
Oral
Parental
Topical
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
By Drug Class:
Pleuromutilin Antibiotic
Cephalosporin
Glycylcycline
Oxazolidinone
Ketolide
Others
By Dose Form:
Solution
Tablet
By Route of Administration
Oral
Parental
Topical
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
By Drug Class:
Pleuromutilin Antibiotic
Cephalosporin
Glycylcycline
Oxazolidinone
Ketolide
Others
By Dose Form:
Solution
Tablet
By Route of Administration
Oral
Parental
Topical
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
GCC
Israel
Rest of Middle East
Africa
By Drug Class:
Pleuromutilin Antibiotic
Cephalosporin
Glycylcycline
Oxazolidinone
Ketolide
Others
By Dose Form:
Solution
Tablet
By Route of Administration
Oral
Parental
Topical
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country/Region:
South Africa
Central Africa
North Africa
Company Profiles
Nabriva Therapeutics*
Company Overview
Product Portfolio
Financial Performance
Key Highlights
Market Strategies
Paratek Pharmaceuticals, Inc.
Melinta Therapeutics, Inc.
Allergan plc
Bayer AG
Lupin Pharmaceuticals, Inc.
Mylan N.V.
Sanofi S.A.
Pfizer Inc.
Dainippon Sumitomo Pharma
Takeda Pharmaceutical Company Limited
Basilea Pharmaceutica International AG
“*” marked represents similar segmentation in other categories in the respective section.